Ensuring cardiovascular safety is an integral component of the drug development process. Early detection of potential cardiac risks—such as lengthening of the QT interval and other ECG abnormalities—with increasing drug exposure is essential to protecting the safety of trial participants. Additionally, a well-executed Concentration-QTc (C-QTc) analysis that establishes a safe therapeutic window has the potential to mitigate the cardiac liability risks during later phase trials of the developmental program. Achieving this milestone while maintaining scientific rigor and development efficiency is a challenge within the industry.
In May 2005, implemented ICH E14 guidelines aimed to improve the cardiovascular safety of investigational drugs. These guidelines provided a framework for conducting Thorough QT (TQT) studies, which became the standard for evaluating a drug’s impact on the heart rate corrected QT (QTc) interval, providing critical insight into cardiovascular safety.
This evolving space, with periodically updated guidelines, has had a recent shift from traditional TQT studies to C-QTc.
According to the Journal of Pharmacokinetics and Pharmacodynamics, “Based on QT study reports reviewed by the FDA between 2016 and 2024, changes to the E14 guideline have resulted in a 34% decrease in the proportion of TQT studies, while the use of C-QTc analysis as the primary analysis has significantly increased.”
Compared to TQT studies, early execution of C-QTc analysis provides a more streamlined approach with faster, more efficient, and cost-effective safety assessments that align with regulatory expectations and guidance. This evolution marks a pivotal advancement in the industry’s approach to cardiovascular safety. Successfully executing a C-QTc analysis requires the seamless integration of specialized clinical operations, technical ECG expertise, advanced biometrics, and focused reporting. To maximize the advantages of C-QTc analysis, partnering with a CRO that offers integrated services and seamless execution aligned with FDA expectations is essential to ensuring both scientific integrity and operational excellence.
Protocol
A C-QTc analysis is only as good as the quality of the underlying data. This process starts before stepping into the clinic during the protocol development stage. While drafting the protocol, Medpace’s seamless collaboration among subject-matter experts ensures dedicated attention is given to the protocol, enabling it to meet the demands of rigorous synchronization of high frequency ECG collection and pharmacokinetic sampling. Once the protocol has been reviewed by our dedicated subject-matter experts, the trial is carried out in Medpace’s newly built, state-of-the-art clinical pharmacology unit.
Medpace Clinical Pharmacology Unit
Medpace Clinical Pharmacology Unit (MCPU) is located on the Medpace campus, right next to the Medpace Core Lab, Central Lab, and Bioanalytical Lab. It has been operational since 2008 and has extensive experience of conducting FIH along with several TQT studies. It has 85 beds split into 4 clinical units. Each unit is self-sufficient, consisting of sleeping, recreational, dining areas, bathrooms, and a nursing station. All 4 clinical units are equipped with a state-of-the-art cardiac monitoring system that can monitor up to 36 subjects simultaneously. Trained and experienced physicians and nursing staff can provide around-the-clock Telemetry and Holter monitoring.
With the launch of a newly built, state-of-the-art clinical pharmacology unit, Medpace strengthens its position as a strategic early phase partner, delivering integration, scientific precision, and operational control that translates early insight into downstream success. This new unit was designed to meet the evolving demands of early phase clinical research: more intensive protocols, more nuanced endpoints, and more integrated data needs.
Medpace Core Labs
When working with the MCPU, Medpace Core Labs (MCL) extracts the Triplicate 12 Lead ECGs directly from the Telemetry system files. When working with other sites or larger later Phase studies, MCL provides sites with 12 Lead Holter devices capable of 48 hours of continuous recording of ECG waveform data in clinical settings, which can be securely uploaded to the MCL database. MCL facilitates required training and qualification for each site to ensure consistency and quality capture of data. Once subject data is received, the MCL system converts files into a format from which ECGs are extracted corresponding to protocol PK timepoints.
Dedicated Medpace medical experts review the quality of the data, make measurements, and provide interpretations within the MCL database in accordance with ICH E14 Guidance. To support robust C-QTc analyses, MCL applies rigorous accuracy and precision standards across all extracted intervals, ensuring reproducible measurements that can withstand regulatory scrutiny. The team also maintains close oversight of dosing schedules and cohort progression to confirm that ECG extractions align with protocol-defined PK sampling and dose administration windows. MCL is able to provide the extracted ECG files in a format suitable for FDA warehouse submission.
Biometrics
The C-QTc analysis is inherently collaborative, requiring a specialized team of Biostatistics, Clinical Pharmacology, and Medical Experts. Medpace’s advanced Biometrics Team ensures seamless integration and compilation of data from ECG and PK concentrations to build model(s) to assess the relationship (or lack thereof) between drug exposure and any potential change in QTc interval. This integrated approach ensures that the submission-ready tables, figures, and listings (TFLs) accurately reflect the drug exposure-response profile regarding cardiac safety.
Report
Following TFL generation, Medpace’s team of clinical experts are able to take the complex modeling results and provide tangible clinical interpretations of the findings for downstream program guidance. This cardiac safety report can be either included in the greater clinical study report (CSR) or appended as a stand-alone report.
Conclusion
The Future of C-QTc Analysis
As cardiovascular safety continues to remain an integral part of clinical development and the landscape continues to evolve, staying current with emerging approaches is essential for maintaining a competitive advantage. The growing adoption of C-QTc underscores a broader shift toward data-driven approaches that enhance efficiency without compromising patient safety. Partnering with a CRO who remains at the forefront of these advancements can help Sponsors navigate the complexities involved, ultimately leading to seamless trial execution and accelerated timelines.
Interested in learning more? Contact our collaborative team of experts to learn how Medpace can support your upcoming clinical development plans with C-QTc analysis.
